Vaxart (OTCMKTS:VXRT) Announces Quarterly Earnings Results, Hits Expectations

Vaxart (OTCMKTS:VXRT) released its earnings results on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02, Zacks reports. Vaxart had a return on equity of 75.49% and a net margin of 14.51%.The business had revenue of $39.23 million for the quarter, compared to analyst estimates of $65.50 million.

Vaxart Stock Down 5.4%

Shares of Vaxart stock traded down $0.04 on Friday, hitting $0.70. The stock had a trading volume of 691,277 shares, compared to its average volume of 433,090. Vaxart has a twelve month low of $0.26 and a twelve month high of $0.84. The business’s 50 day moving average is $0.70 and its two-hundred day moving average is $0.54. The stock has a market cap of $169.38 million, a price-to-earnings ratio of 4.67 and a beta of 1.18.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Vaxart to a “buy” rating in a report on Friday, January 23rd.

Institutional Investors Weigh In On Vaxart

Large investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new stake in Vaxart during the second quarter worth approximately $33,000. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the first quarter worth approximately $31,000. Invesco Ltd. grew its position in Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares in the last quarter. Raymond James Financial Inc. grew its position in Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.